Positive Data, Financial Strategies, Marketing Authorizations, and Collaborations Promote Growth in Biotech Companies - Research Report on Biogen Idec, MannKind, Aegerion, Ariad, and Seattle Genetics Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, July 10, 2013 NEW YORK, July 10, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), MannKind Corp. (NASDAQ: MNKD), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Ariad Pharmaceuticals Inc. (NYSE: ARIA), and Seattle Genetics Inc. (NASDAQ: SGEN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Biogen Idec Inc. Research Report On July 4, 2013, Biogen Idec Inc. (Biogen Idec) and Swedish Orphan Biovitrum AB (publ) (Sobi) released new data supporting the clinical and safety profile of ELOCTATE, a long-lasting recombinant factor VIII candidate for hemophilia A. Glenn Pierce, M.D., Ph.D., Senior Vice President of Global Medical Affairs and Chief Medical Officer of Biogen Idec's Hemophilia Therapeutic Area, said, "We are excited to share these new data, which include patients' and physicians' assessment of ELOCTATE's efficacy in treating bleeding episodes and in controlling bleeding during surgery." Pierce continued, "The A-LONG data presented at ISTH support the potential of ELOCTATE to enable longer intervals between prophylactic (preventative) injections compared to the current standard of care." The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/b35f_BIIB] -- MannKind Corp. Research Report On July 1, 2013, MannKind Corp. (MannKind) announced that it has entered into a secured financing with affiliates of Deerfield Management Company L.P. (Deerfield). MannKind reported that Deerfield has committed to purchase up to $160 million of its senior secured notes under the financing agreement. Alfred E. Mann, CEO of MannKind, commented, "We worked with Deerfield to structure a facility that aligns with our near- and long-term strategy to achieve important development, commercial and strategic milestones while minimizing near term dilution." Mann added, "We are encouraged by Deerfield's confidence in the potential of AFREZZA." The Full Research Report on MannKind Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/0b44_MNKD] -- Aegerion Pharmaceuticals, Inc. Research Report On July 5, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that on July 1, 2013, it granted stock options to purchase an aggregate of 19,700 shares of common stock to five new employees under the inducement stock option program. The Company also reported that the Compensation Committee of the Company's Board of Directors approved the reservation of 1 million shares of common stock to be used exclusively for the grant of non-qualified stock options to individuals who were not previously an employee or non-employee director of Aegerion (or following a bona fide period of non-employment), as an inducement new hire stock option award material to an individual's entry into employment within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (Inducement Stock Options). The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/a1f4_AEGR] -- Ariad Pharmaceuticals Inc. Research Report On July 2, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced that Iclusig (ponatinib) has been granted marketing authorization by the European Commission (EC) as an orphan medicinal product for two indications: for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, and secondly. for the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Harvey J. Berger, M.D., Chairman and CEO of Ariad, commented, "We are delighted by the rapid approval of Iclusig in Europe and will now work closely with the national health authorities to make Iclusig available to Philadelphia-positive leukemia patients as quickly as possible." The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/1015_ARIA] -- Seattle Genetics Inc. Research Report On June 27, 2013, Seattle Genetics Inc. (Seattle Genetics) and Agensys, Inc., announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement. Eric L. Dobmeier, Chief Operating Officer of Seattle Genetics, stated, "Through our collaboration and co-development agreements with companies like Agensys/Astellas, Seattle Genetics continues to enhance its ability to innovate by combining our industry-leading ADC technology with proprietary cancer targets and antibodies to develop potential new treatments for patients with cancer." Dobmeier added, "ADCs represent a novel therapeutic approach, and through our pipeline and collaborations more than half of the ADC candidates in clinical development utilize our technology. We look forward to working with Agensys/Astellas to advance ASG-15ME." The Full Research Report on Seattle Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/f796_SGEN] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Positive Data, Financial Strategies, Marketing Authorizations, and Collaborations Promote Growth in Biotech Companies - Research
Press spacebar to pause and continue. Press esc to stop.